While previous studies have confirmed combined MEK and STAT3 inhibition effective in overcoming therapeutic resistance and altering stromal architecture, a present study has determined that MEK/STAT therapy plays an active role in bypassing immunotherapy resistance in PDAC as well, decreasing stromal inflammation and increasing cancer-associated fibroblasts with mesenchymal properties [66]. Here, MAP2K7 is linked to cancer.